Physician profile
Ann Hedderman
NPI 1801847603
$6,104.88
in general payments reported to CMS, 2019-2025
63 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $50.18 · 2021: $1,028 · 2022: $1,059 · 2023: $1,080 · 2024: $1,324 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,712 · Education: $36.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.03 |
| Education | $36.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $450.17 | 2021-2025 | |
| Janssen Biotech, INC. | $402.26 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $358.25 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $343.21 | 2021-2025 | Fruzaqla, Alunbrig, Iclusig |
| Incyte Corporation | $300.53 | 2020-2024 | Monjuvi, Pemazyre, Jakafi |
| Seagen INC. | $237.13 | 2021-2023 | Adcetris |
| Genzyme Corporation | $224.82 | 2021-2025 | |
| Celgene Corporation | $211.79 | 2021-2024 | Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $191.09 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $176.78 | 2021-2023 | Epkinly, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $157.63 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Amgen INC. | $154.44 | 2021-2024 | Blincyto, Kyprolis, Vectibix |
| Astellas Pharma US INC | $144.55 | 2023-2025 | Padcev, Xtandi, Xospata |
| Ipsen Biopharmaceuticals, INC | $132.80 | 2023-2025 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $128.80 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Hedderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.